

Summary of status of development and availability of A(H9N2) candidate vaccine viruses and potency testing reagents

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise indicated all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)

27 February 2026

Candidate vaccine viruses*

Antigenic prototype	Clade	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from	
A/Oman/2747/2019	G1	Wild type virus			WHO CCs	
		IDCDC-RG66A*	Reverse genetics	CDC, USA	CDC, USA	
A/Oman/2747/2019		Wild type virus			WHO CCs	
		IDCDC-RG66A*	Reverse genetics	CDC, USA	CDC, USA	
A/Bangladesh/994/2011		Wild type virus			WHO CCs	
		IDCDC-RG31*	Reverse genetics	CDC, USA	CDC, USA	
A/Hong Kong/33982/2009		Wild type virus			WHO CCs	
		IBCDC-RG26*	Reverse genetics	CDC, USA	CDC, USA	
A/Hong Kong/1073/99		Wild type virus			MHRA, UK	
A/Anhui-Lujiang/39/2018		Y280/G9	Wild type virus			CCDC, China
			IDCDC-RG61A*	Reverse genetics	CCDC, China CDC, USA	CDC, USA
A/Hong Kong/308/2014			Wild type virus			WHO CCs
	SJ008*		Reverse genetics	SJCRH, USA	SJCRH, USA	
A/chicken/Hong Kong/G9/97	Wild type virus			WHO CCs		
	NIBRG-91*		Reverse genetics	MHRA, UK	MHRA, UK	
	IBCDC-2*		Classical reassortant	CDC, USA	CDC, USA	

* These viruses are candidate vaccine viruses which have passed relevant safety testing. They can be handled under BSL-2 enhanced containment¹.

¹ [Guidelines for the safe development and production of vaccines to human pandemic influenza viruses and influenza viruses with pandemic potential, Annex 3, TRS No 1016 \(who.int\)](#)

Candidate vaccine viruses in preparation

Antigenic prototype	Clade	Type	Developing Institute	Available from
A/Anhui-Lujiang/39/2018	Y280/G9	Conventional	MHRA, UK	Pending
A/Anhui-Tianjiaan/11086/2022	Y280/G9	Reverse genetics	CDC, USA	Pending
A/Hunan/40087/2025[‡]	Y280/G9	Reverse genetics	CCDC, China	Pending

[‡] New CVV shown in blue

Institutes contact details for candidate vaccine virus orders and other information:

CCDC: fluchina@ivdc.chinacdc.cn

CDC: cvvrequest@cdc.gov (Subject: CVV request)

MHRA: standards@mhra.gov.uk or enquiries@mhra.gov.uk

SJCRH: richard.webby@stjude.org

WHO CCs: <https://www.who.int/initiatives/global-influenza-surveillance-and-response-system/who-collaboration-center-erl?CxitPEOtTWx0xUd5TJdODSXcnyJqzYd7FZeivpn7xcl=>

Reference antigens (freeze-dried)

Parent virus	Starting Materials		Ref Ag / Lot number	Unitage (µg HA/mL)	Available from
	CVV	Egg or Cell			
A/chicken/Hong Kong/G9/97	NIBRG-91	Egg	08/228	84	MHRA, UK
A/Hong Kong/1073/99	Wild-type	Egg	08/208	80	
A/Anhui-Lujiang/39/2018	SeqHS_Sys22_03.5	cell	H9-Ag-2211	112	CBER/FDA, USA
A/Anhui-Lujiang/39/2018	IDCDC-RG61A	Egg	2024/147B	81	TGA, Australia

Sheep antisera

Purified HA from		Order Lot number	Available from
Parent virus	Egg or Cell		
A/Hong Kong/1073/99	Egg	07/146	MHRA, UK
		10/214 [§]	
A/chicken/Hong Kong/G9/97		08/202	
A/Anhui-Lujiang/39/2018-like	rHA	AS456	TGA, Australia

[§] Anti NA serum for tests of neuraminidase identification

WHO Essential Regulatory Laboratories (ERLs) contact details for reagent orders and other information:

MHRA: standards@mhra.gov.uk or enquiries@mhra.gov.uk

TGA: influenza.reagents@tga.gov.au

For reagents available from **CBER**, email CBERShippingRequests@fda.hhs.gov.

For information of other type and subtype candidate vaccine viruses and potency testing reagents, please go to: (<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/zoonotic-influenza-viruses-and-candidate-vaccine-viruses>).

For general enquiries, please contact gisrs-whohq@who.int